alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › lithium-treatment

lithium-treatment

4 studies tagged lithium-treatment, dated 2000-03-01 to 2012-02-09. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype 2012-02-09
  2. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies 2005-10-14
  3. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model 2003-08-01

Studies

4 studies carry this tag.

Date range

2000 to 2012

Top journals

  • Acta neuropathologica 1
  • European journal of pharmacology 1
  • Journal of Alzheimer's disease : JAD 1
  • PloS one 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. PloS one 2012-02-09 Drug development

    Lithium is an anti-psychotic that has been shown to prevent the hyperphosphorylation of tau protein through the inhibition of glycogen-synthase kinase 3-beta (GSK3β).

  2. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Acta neuropathologica 2005-10-14 Drug development

    Lithium, a widely used drug for treating affective disorders, is known to inhibit glycogen synthase kinase-3 (GSK-3), which is one of the major tau kinases.

  3. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Alzheimer's disease : JAD 2003-08-01 Drug development

    Tau protein hyperphosphorylation and aggregation into neurofibrillary tangles are characteristic features of several neurodegenerative disorders referred to as tauopathies.

  4. beta-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. European journal of pharmacology 2000-03-01 Drug development

    Treatment of rat pheochromocytoma cells (PC 12) cells with beta-amyloid peptide-(1-42) for 24 h induced a concentration-dependent decrease in cellular redox activity in the dose range of 1 to 20 microM.

All topic tags with their study counts